Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain.
Polymeric interstitial chemotherapy increases survival of humans with recurrent gliomas and animals with transplanted tumors in the brain, but the relationship between rates of drug release from polymer implants and drug concentration in brain tissue is unknown. This work presents a pharmacokinetic framework for application of this new modality of chemotherapy delivery in primates. Either [3H]carmustine, 4-hydroperoxycyclophosphamide (4-HC), or paclitaxel was encapsulated in a polyanhydride pellet (28-41 microCi/animal, 40 mg/animal), which was implanted intracranially in cynomolgus monkeys (Macaca fascicularis); (n = 17) for up to 30 days. Drug concentrations in the brain, blood, and cerebrospinal fluid were measured by quantitative autoradiography, TLC, and scintillation counting. High drug concentrations (0.5-3.5 mM for carmustine, 0.3-0.4 mM for 4-HC, and 0.2-1.0 mM for paclitaxel) were measured within the first 3 mm from the polymer implant; significant (0.4 microM for carmustine, 3 microM for 4-HC, and 0.6 microM for paclitaxel) concentrations were measured up to approximately 5 cm from the implant as long as 30 days after implantation. Pharmacokinetic analysis indicated that tissue exposure to carmustine area under concentration-time curve achieved by polymeric delivery was 4-1200 times higher than that produced by i.v. administration of a higher dose.
Fung
L K
LK
School of Chemical Engineering, Cornell University, Ithaca, New York 14853, USA.
Ewend
M G
MG
Sills
A
A
Sipos
E P
EP
Thompson
R
R
Watts
M
M
Colvin
O M
OM
Brem
H
H
Saltzman
W M
WM
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001673:Biodegradation, Environmental; D001921:Brain; D002214:Capsules; D002330:Carmustine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004343:Drug Implants; D008252:Macaca fascicularis; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011108:Polymers
C093853:4-hydroxyperoxycyclophosphamide; D000970:Antineoplastic Agents; D002214:Capsules; D004343:Drug Implants; D011108:Polymers; D003520:Cyclophosphamide; D017239:Paclitaxel; D002330:Carmustine